India's pharmaceutical industry is making strategic investments in active pharmaceutical ingredients (APIs) and advanced therapies. This move aims to reduce reliance on imports and focus on high-value medicines. The shift is driven by the need for supply-chain resilience and enhanced manufacturing capabilities. Recent data shows strong growth in the domestic market and a rise in pharmaceutical exports, indicating a positive trend for local manufacturers. For more details, refer to the original publication.
Read the original article